|
- AstraZeneca | Cafepharma
AstraZeneca on Thursday appointed company insider Rick Suarez as the head of its U S biopharmaceuticals unit to lead the drugmaker's $50 billion investment plan in the company's largest market
- AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device Sales . . .
Anonymous board for AstraZeneca We’ve seen a growing number of threads touching on AI tools—everything from ChatGPT to internal company initiatives—but mostly in bits and pieces We’re running a short, anonymous survey to better understand how pharma reps (and others in the industry) are actually using AI today, what concerns they have, and what kind of guidance would be most useful
- Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous discussion boards for pharmaceutical sales, medical device sales, lab diagnostics sales
- July 24 2025 - AstraZeneca drug acquired in Alexion deal succeeds in . . .
AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trialAstraZeneca boardPharma giant Roche sees income soar in first halfRoche boardNovartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapiesNovartis boardHow Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab
- Cafepharma News
Latest news and updates on pharmaceutical and medical sales, including breakthrough treatments and industry trends
- Pfizer | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous board for Pfizer We’ve seen a growing number of threads touching on AI tools—everything from ChatGPT to internal company initiatives—but mostly in bits and pieces We’re running a short, anonymous survey to better understand how pharma reps (and others in the industry) are actually using AI today, what concerns they have, and what kind of guidance would be most useful The
- Cafepharma - Home | pharma sales, device sales, lab sales | Cafepharma
JPM26: AstraZeneca's $80B revenue target 'very much within reach,' CFO says Fierce Pharma Wednesday, January 14, 2026 - 11:55 am AstraZeneca, JPMHC 2026 AstraZeneca board JPM26: As lenacapavir momentum builds, Gilead eyes new deals from a 'position of strength' Fierce Biotech
- AstraZeneca’s Fasenra meets primary endpoint in Phase III rare . . .
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with eosinophilic granulomatosis with polyangiitis
|
|
|